These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15093601)

  • 61. Development of sustained release gastroretentive drug delivery system for ofloxacin: in vitro and in vivo evaluation.
    Chavanpatil M; Jain P; Chaudhari S; Shear R; Vavia P
    Int J Pharm; 2005 Nov; 304(1-2):178-84. PubMed ID: 16198522
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Optimization and evaluation of a new antischistosomal drug QH917 self-microemulsifying drug delivery system].
    Zhang JY; Gan Y; Gan L; Zhu CL; Pan WS
    Yao Xue Xue Bao; 2007 Apr; 42(4):434-9. PubMed ID: 17633215
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Novel design of osmotic chitosan capsules characterized by asymmetric membrane structure for in situ formation of delivery orifice.
    Wang GM; Chen CH; Ho HO; Wang SS; Sheu MT
    Int J Pharm; 2006 Aug; 319(1-2):71-81. PubMed ID: 16701971
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Development of pH- and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon.
    Krishnamachari Y; Madan P; Lin S
    Int J Pharm; 2007 Jun; 338(1-2):238-47. PubMed ID: 17368982
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of binder additives on terbutaline hydrogels of alpha-PVA/NaCl/H(2)O system in drug delivery: I. Effect of gelatin and soluble starch.
    Shaheen SM; Takezoe K; Yamaura K
    Biomed Mater Eng; 2004; 14(4):371-82. PubMed ID: 15472386
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Modulated release metoprolol succinate formulation based on ionic interactions: in vivo proof of concept.
    Ravishankar H; Patil P; Samel A; Petereit HU; Lizio R; Iyer-Chavan J
    J Control Release; 2006 Mar; 111(1-2):65-72. PubMed ID: 16446006
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Applicability of (SBE)7m-beta-CD in controlled-porosity osmotic pump tablets (OPTs).
    Okimoto K; Tokunaga Y; Ibuki R; Irie T; Uekama K; Rajewski RA; Stella VJ
    Int J Pharm; 2004 Nov; 286(1-2):81-8. PubMed ID: 15501004
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Phase transited and vapor-induced dual capsular system (DCS) for achieving delayed and osmotic release of cefadroxil.
    Philip AK; Philip B
    Pharm Dev Technol; 2011 Oct; 16(5):457-65. PubMed ID: 20482448
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Approach to design push-pull osmotic pumps.
    Malaterre V; Ogorka J; Loggia N; Gurny R
    Int J Pharm; 2009 Jul; 376(1-2):56-62. PubMed ID: 19383532
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Osmotic-controlled release oral delivery system (OROS) paliperidone-related pruritic rash.
    Liu CT; Hsieh TH
    J Clin Psychopharmacol; 2011 Aug; 31(4):525-6. PubMed ID: 21720225
    [No Abstract]   [Full Text] [Related]  

  • 71. Osmotically controlled pulsatile release capsule of montelukast sodium for chronotherapy: statistical optimization, in vitro and in vivo evaluation.
    Ranjan OP; Nayak UY; Reddy MS; Dengale SJ; Musmade PB; Udupa N
    Drug Deliv; 2014 Nov; 21(7):509-18. PubMed ID: 24215165
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Nano-suspension coating as a technique to modulate the drug release from controlled porosity osmotic pumps for a soluble agent.
    Bahari LA; Javadzadeh Y; Jalali MB; Johari P; Nokhodchi A; Shokri J
    Colloids Surf B Biointerfaces; 2017 May; 153():27-33. PubMed ID: 28208062
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Novel microporous resin-based polymer device for sustained glipizide release: Production, characterization and pharmacokinetic study.
    Liu H; Zhang B; Chen Y; Cui Z; Hu L
    Biomed Pharmacother; 2022 Nov; 155():113772. PubMed ID: 36271554
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Osmotically regulated flow of flurbiprofen through in situ formed asymmetric membrane capsule.
    Philip AK
    Curr Drug Deliv; 2008 Apr; 5(2):127-32. PubMed ID: 18393815
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Formulation aspects in the development of osmotically controlled oral drug delivery systems.
    Verma RK; Krishna DM; Garg S
    J Control Release; 2002 Feb; 79(1-3):7-27. PubMed ID: 11853915
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Design and development of controlled porosity osmotic tablet of diltiazem hydrochloride.
    Shahi SR; Zadbuke NS; Gulecha B; Shivanikar SS; Shinde SB
    J Adv Pharm Technol Res; 2012 Oct; 3(4):229-36. PubMed ID: 23378944
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Slow-release delivery systems.
    Squire I; Lees K
    Practitioner; 1992 Nov; 236(1520):1088-91. PubMed ID: 1305755
    [No Abstract]   [Full Text] [Related]  

  • 78. Development and optimization of osmotically controlled asymmetric membrane capsules for delivery of solid dispersion of lycopene.
    Jain N; Sareen R; Mahindroo N; Dhar KL
    ScientificWorldJournal; 2014; 2014():438528. PubMed ID: 24605053
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Formulation and evaluation of release and swelling mechanism of a water-in-oil emulsion using factorial design.
    Bjerregaard S; Söderberg I; Vermehren C; Frokjaer S
    Int J Pharm; 1999 Dec; 193(1):1-11. PubMed ID: 10581416
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Predetermination of burst times of elastoplastic osmotic capsules.
    Jain KMH; Siegel RA
    J Control Release; 2023 May; 357():422-431. PubMed ID: 36940773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.